Ubs Oconnor LLC Terns Pharmaceuticals, Inc. Transaction History

Ubs Oconnor LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$2.0 - $4.1 $125,050 - $256,352	-62,525 Reduced 18.6%	273,619 $1.02 Million
Q1 2025 May 15, 2025	BUY	$2.76 - $5.79 $540,529 - $1.13 Million	195,844 Added 139.59%	336,144 $927,000
Q4 2024 Feb 14, 2025	BUY	$5.53 - $8.36 $510,419 - $771,628	92,300 Added 192.29%	140,300 $782,000
Q3 2024 Nov 14, 2024	BUY	$6.49 - $10.8 $311,520 - $518,400	48,000 New	48,000 $400,000

152

90.3M

574K

41.6K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $846M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.